| Ticker Details |
Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company. It discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases.
|
| IPO Date: |
December 7, 2000 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$563.83M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.23 | 2.81%
|
| Avg Daily Range (30 D): |
$0.56 | 1.97%
|
| Avg Daily Range (90 D): |
$0.86 | 2.28%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.98M |
| Avg Daily Volume (30 D): |
.3M |
| Avg Daily Volume (90 D): |
.33M |
| Trade Size |
| Avg Trade Size (Sh.): |
220 |
| Avg Trade Size (Sh.) (30 D): |
50 |
| Avg Trade Size (Sh.) (90 D): |
50 |
| Institutional Trades |
| Total Institutional Trades: |
1,850 |
| Avg Institutional Trade: |
$1.44M |
| Avg Institutional Trade (30 D): |
$1.66M |
| Avg Institutional Trade (90 D): |
$2M |
| Avg Institutional Trade Volume: |
.04M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.65M |
| Avg Closing Trade (30 D): |
$1.79M |
| Avg Closing Trade (90 D): |
$2.22M |
| Avg Closing Volume: |
56.91K |
|
|
| Financials |
| |
TTM |
Q4 2025 |
FY 2025 |
|
Basic EPS
|
$20.4
|
$14.88
|
$20.4
|
|
Diluted EPS
|
$19.48
|
$14.1
|
$19.48
|
|
Revenue
|
$294.28M
|
$69.8M
|
$294.28M
|
|
Gross Profit
|
$274.66M
|
$63.85M
|
$274.66M
|
|
Net Income / Loss
|
$367.02M
|
$268.07M
|
$367.02M
|
|
Operating Income / Loss
|
$125.47M
|
$23.17M
|
$125.47M
|
|
Cost of Revenue
|
$19.62M
|
$5.96M
|
$19.62M
|
|
Net Cash Flow
|
$-16.11M
|
$-7.95M
|
$-16.11M
|
|
PE Ratio
|
1.51
|
|
|
| Splits |
|
Jun 27, 2024
|
1:10
|
|
Jun 25, 2003
|
1:9
|
|
|
|
